Relationship Between Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 with Chemotherapy Sensitivity in Glioma Cells
DING Jian-jun,GUO Zhen-tao,LIU Bao-hui,YU Jun-hua,YI Wei,JI Bao-wei,JI Zhen-gang,WU Li-quan,TIAN Dao-feng,CHEN Qian-xue
DOI: https://doi.org/10.3760/cma.j.issn.1001-9030.2012.07.050
2012-01-01
Abstract:Objective To investigate the relationship between leucine-rich repeats and immunoglobulin-like domains 1 ( LRIG1 ) with chemotherapy sensitivity in glioma cells.Methods Temozolomide (TMZ) resistant cell line was constructed and the expression of LRIG1 was detected by using reverse transcription-polymerase chain reaction (RT-PCR).The multidrug resistance was measured by using cell counting Kit-8 (CCK-8).LRIG1 plasmid was transfected into the multidrug resistant cells,and chemotherapy sensitivity was tested.Results Multidrug resistant cell line was constructed and the cell line had resistance to temozolomide,adriamycin,cyclophosphamide,etoposide and vincristine sulfate.The inhibition rate of these drugs used to U251 cell line was as follows:( 19.30 ± 0.04 ) ％,( 39.90 ± 0.13 ) ％,( 28.10 ± 0.09)％,(66.20±0.02)％,(26.30±0.11)％,and that to U251/TR was as follows:(3.20±0.03)％,(15.30±0.09)％,(4.10 ±0.03)％,(45.60 ±0.10)％,(10.80±0.04)％.The difference was statistically significant between U251 and U251/TR.(P ＜0.05).The expression of LRIG1 was decreased in U251/TR compared to U251 cells,and the resistance was abolished when plasmid of LRIG1 was transfected into the multidrug resistant cells.The inhibition rate of TMZ,VP16,vincristine,cyclophosphamide and doxorubicin used to bland group (resistant cell line) was (2.60 ± 0.02)％,( 3.30 ± 0.02 ) ％,(9.50 ± 0.06) ％,( 2.20 ±0.05) ％ and ( 2.90 ± 0.03) ％,and that of these drugs used to transfected group was ( 19.10 ±0.34 ) ％,(38.20 ± 0.53) ％,(29.10 ± 0.25 ) ％,( 15.20 ± 0.55 ) ％,and ( 17.40 ± 0.41 ) ％ respectively.The difference was statistically significant ( P ＜ 0.05 ).Conclusion The expression level of LRIG1 was associated with the chemotherapy sensitivity in astrocytoma.LRIG1 was associated with the multidrug resistance of glioma.